...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: AGM - Jan 7, 2016 - Details

masila, thanks very much for your excellent detailed report! That was quite a bit of work and it's greatly appreciated!

It was interesting to note that...

"Current Zenith shareholders will own shares of both ZCC and ZEL."

I still don't have much of a feel for how current share ownership would translate into ownership in an IPO or asset sale. I'm still thinking substantial dilution, but it's hard to tell. BUT, overall, the future looks promising.

Share
New Message
Please login to post a reply